In the Spring issue of the Journal for Clinical Studies, Rob Masson, CEO of The DPO Centre, breaks down the four important data protection factors that need to be considered when managing the personal data associated with an EU/UK clinical trial.
The pharmaceutical industry is heavily regulated, therefore businesses in this sector are used to having to follow a variety of tight rules and regulations during the research, testing, and production of new drugs. Clinical trials, however, are unquestionably where it is most pertinent when considering privacy and data protection laws. A substantial amount of sensitive personal data must be processed in order to prove a drug’s safety and effectiveness, which necessitates careful consideration of data privacy issues. The General Data Protection Regulation, often regarded as the “gold standard” for protecting individuals’ personal data, will be at the centre of such concerns for clinical trials involving participants located in the EU or the UK. Read the full article here.